Advanced Genomics Platform for Next-Generation Cancer Therapies



Investor Presentation May 2021

Forward-Looking Statements

This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations, financial condition, business strategy, plans, and objectives of management for future operations of Personalis, Inc. ("Personalis" or the "Company"), future market sizes, potential success of personalized cancer therapies and other drugs, the developing and potential competitive landscape for genomic sequencing platforms, and others, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements, such as the impact of the COVID-19 pandemic on the business and operations of the Company and its customers, expressed or implied by the forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those discussed in Personalis' filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Forms 8-K, 10-K and 10-Q, and in the documents incorporated by reference therein.

In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "predict," "project," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. These statements are only predictions. Personalis has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation, except as required by law.

This presentation also contains estimates and information concerning the Company's industry and business, including estimated market size, projected growth rates of the markets in which Personalis participates, indicative pricing for the Company's products and the prevalence of certain medical conditions. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Personalis.

The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.



Investment Highlights

Large market of ~\$40B for biopharma research, clinical and companion diagnostics, and population sequencing

Market-leading immuno-oncology biomarker platform for tissue & liquid biopsies


Growing NeXT platform adoption by large pharma and advanced biotech companies, including as a partner for prospective therapy development (50 customers as of 1Q'21)

Attractive historical growth and strong cash position

Proven scale with more than 180,000 samples sequenced to-date, with ample capacity

1Q 2021 Highlights

- Achieved record quarterly revenues of \$20.9M in Q1 2021 (+9% YoY growth), despite the negative impacts from the pandemic on customer sample shipments and operations
- ~74% YoY preliminary biopharma revenue growth, fueled by strong adoption of NeXT by both new and existing customers
- In total, 50 customers have placed orders for NeXT as of 3/31/2021, with five of those customers placing their first orders in 1Q 2021
- Initial pilot orders have increased on average from \$50K range in 2018 to hundreds of thousands of dollars
- Announced commercial partnerships with Natera and MapKure, a Beigene joint venture
- Cash, cash equivalents, and short-term investments were \$353MM as of 3/31/2021; added ~\$162MM in cash from common stock offering



2020-2021 Accomplishments

Key Highlights

50 Customers have placed orders for NeXT as of 1Q 2021

- 4 New Product Offerings in 2020
- Commercial team has grown 100% since the IPO and 30% in 2020 alone

Multiple New Partnership and Collaborations

9% YoY Revenue Growth in 1Q 2021

Completed 115,000+ Whole Genomes for VA MVP

Increased Momentum and Adoption by

Biopharma Customers

🙌 Personalis⁻

Key Customer	Wins and Partnerships
--------------	-----------------------

• Customers include a majority of the top ten oneology pharma	\checkmark	Customers include a majority of the top ten oncology pharma
---	--------------	---

- Collaboration with Merck KGaA to identify and develop novel biomarkers for cancer therapies
- CDx partnership with MapKure ,LLC, (JV of Beigene, Ltd.)

 \checkmark

 \checkmark

- Scientific collaboration with Sarepta Therapeutics for rare disease
- Partnership with Natera to provide exome sequencing services for personalized test
- Partnership with Berry Genomics for China lab expansion


New Product Offerings

- NeXT Liquid Biopsy, exome-wide liquid biopsy platform (launched)
- NeXT Personal, also from liquid biopsies (2021 planned launch)
- Cancer whole genome sequencing services (launched 2019); future option to identify ~ 20x more variants for NeXT Personal
- NeXT Dx Test, a comprehensive genomic cancer profiling test enabling advanced composite biomarkers for cancer treatment
- NeXT SHERPA and NEOPS neoantigen prediction capability

2021 Strategic Priorities

- Drive continued growth of NeXT platform and population sequencing with both new and existing customers
- Continue to drive the expansion of our multiple liquid biopsy offering, including:
 - NeXT Liquid Biopsy which was launched in August 2020 and has received several initial customer orders in 2020 with first customer delivery in 1Q 2021
 - Expect to launch of NeXT Personal (MRD Liquid Biopsy offering) in 2021
- Continue to invest in infrastructure and ramp up efforts to obtain clinical and regulatory approval for NeXT Platform
- Continue to enhance and display clinical utility of the NeXT Platform through collaborations
- Expansion of facility capacity and operational footprint
- Expand footprint in China and deepen relationships with the local scientific and regulatory community

Liquid Biopsy Roadmap



Overview of Recently Launched NeXT Liquid Biopsy Platform

Platform Highlights

- Monitors 20,000 genes, or about 40x more genes than the majority of liquid biopsy cancer panels on the market
- Ability to track mutations and detect new mutations over time in response to treatment
- Capabilities will help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development of nextgeneration cancer therapies

Strategic Importance

- Expands TAM into liquid biopsy market
- First product in Company's liquid biopsy product portfolio
- Liquid biopsy results can be paired with NeXT Platform tissue results and provide an unprecedented breadth of data from limited tumor sample
- Comprehensiveness <u>matters</u> for biopharma customers

Several customer orders received with additional discussions ongoing





Cancer drug development & population sequencing are increasingly about data...


... and Personalis is positioned to be a key part of that ecosystem



10

Personalis Provides Proprietary Genomic Information to Customers

Efforts to develop better cancer drugs increase demand for genomic information



Personalis is Transforming the Development of Next-Generation Cancer Therapies


Providing biopharma with more comprehensive molecular data about patient tumors



Notes: Personalis^{, 1.} Reference page 13 and page 14 for TAM

Large Market Opportunity Across Therapy Selection, Monitoring, Clinical Trials, and Population Sequencing

Comprehensive Product Offering in ~\$40BN Current TAM Categories



Rersonalis[®]

1. Company estimate based on 2 million diagnosed cancer patients requiring an initial tissue test at a price of ~\$3,000 per test.

- Company estimate based on 2 million diagnosed patients requiring in-depth monitoring at a test price of \$2,840 per test at a frequency of four times a year
- Company estimate based on 200,000 clinical trial patients requiring an initial tissue test at a price of ~\$3,000 per test and in-depth monitoring at a price of ~\$4,000 per test at a frequency of eight times per year.

Company estimate based on its VA MVP genome sequencing pricing and 2 million individuals per year, based on publicly available reports of population sequencing projects covering over 14 million individuals and an assumed 7-year average project duration

13

Therapy Selection, Monitoring, Clinical Trials TAM Build-Up

	Estimated # of Cancer Patients	x Assumed Testing Needed	x Indicative Price	= Market Opportunity
Clinical Trial Patients	200k/Year ¹	1 Initial Tissue Test	~\$3,000 ⁵	~\$600M
		8x/yr in-depth monitoring ³	~\$4,000 ³	~\$6.4BN
Therapy Selection	2M/Year ²	1 Initial Tissue Test	~\$3,000 ⁵	~\$6BN
Monitoring	2M/Year ²	4x/yr in-depth monitoring ⁴	~\$2,840 ⁶	~\$22.72BN

Notes:

1. Estimated 200,000 enrolled in clinical trials based on Company review of ClincialTrials.gov data.

2. U.S. National Cancer Institute estimate that 2.2 million patients are actively receiving care. 2 million per year, net clinical trial patients.

3. Company estimate for pricing is based on the Company's historical standard pricing for tissue samples and anticipated pricing for liquid biopsy samples. Company estimate for frequency is based on frequency of monitoring in a clinical trial protocol used by Merck in a recent immune-oncology drug trial and assumes that monitoring would occur every six weeks.

Company estimate based on expected usage for Signatera, a personalized circulating tumor DNA monitoring assay to support optimal cancer treatment planning, reported by Natera on its Q2 2020 earnings call.
 CMS payment rate for tissue-based cancer diagnostic test – based on CPT code 81455.

Personalis[®] 5.

Currently no approved the solution of the control of the technical similarity to Natera's kidney transplant rejection monitoring test, Prospera, which also monitors cell free DNA from blood plasma and which receives coverage at \$2,840, based on assumption that similar coverage could be sought for cancer monitoring genetic tests not currently subject to coverage.

Operational Excellence

180,000+ human samples sequenced to date

Significant focus on process development including with laboratory automation, to drive margin expansion

Differentiated QMS and Regulatory Credentials CLIA / CAP, NY State¹ & FDA² - all at exome scale

Headquartered in Menlo Park, CA

250+ employees


Specialized commercial team has grown 100% since IPO

Intellectual Property Protection

including 10 issued U.S. and 2 issued foreign patents

🙌 Personalis

Notes:
 We maintain a current license with the New York State Department of Health for our laboratory
 We have filed a Device Master File with the FDA.



Equipment sequencing capacity as of Q1 each year


15

Experienced Leadership Team John West Richard Chen, M.D., M.S. Stephen Moore Aaron Tachibana Chief Scientific Officer General Counsel President, Chief Executive Officer & Director Chief Financial Officer **INGENUITY** Stanford Medicine PACIFIC BIOSCIENCES* AB applied biosystems illumina SoleXa **JDSU PERICOM** LUMENTUM MANAGEMENT TEAM LYNX Christian Haudenschild, Ph.D. VP Operations illumina SoleXa Stephane Mouradian VP Business Development illumina[®] Y Caliper Scientific Susan Moriconi VP People & CHRO 🕚 Omnicell Carol Tillis VP Finance and Administration Rena McClory, Ph.D. VP Marketing RainDance AB applied biosystems illumina[®] 💥 Agilent Lloyd Hsu VP Software Engineering 🔶 Informatica TIBC NON-EMPLOYEE DIRECTORS **O Forty Seven** Chairman of the Board Jonathan MacQuitty, Ph.D. Lightspeed A. Blaine Bowman Director D DIONEX illumina[®] **SOFINNOVA** Alan Colowick, M.D. Director **AMGEN** HUMAN LONGEVITY, Celgene Karin Eastham Director deron illumina[®] Veracyte. **NEKTAR** natus (IRIDEX Kenneth Ludlum Director ♦ CareDx⁻ Woodrow Myers, M.D. BlueCross BlueShield Director **C**²**R**IZON HAVENCREST Paul Ricci Director WARBURG PINCUS Lightspeed




Personalis is Purpose-Built for Biopharma

Our comprehensive solution represents the next step in biopharmaceutical research



Diagnostic Panels Utilize Human Tissue But Aren't Comprehensive



Proprietary Platform Maximizes Insights from a Single Sample

Patient Tumor Samples Are Often Extremely Limited



Traditional Process Multiple Samples | Multiple Vendors | Multiple Assays


- Image: Targeted Therapy Panel (often 50 to 500 genes)
- Neoantigen Identification from Exome
- Expression Data from Array
- TCR / Immune Cell Repertoire
- MSI-Testing
- Oncoviral Testing
- Remaining Sample, if any, Sent to Discovery and Translational Teams
- / HLA-Testing





20

Personalis Provides a More Complete Picture of the Cancer, Which is Expected to Lead to Improved Clinical Development Success Rates



Viewing a singular aspect of tumor biology limits conclusions



Personalis Note: 1. Biotechnology Innovation Organization (BIO), Biomedtracker, and Amplion "Clinical Development Success Rates 2006-2015" (Jun-2016).

Enabling Comprehensive Data for Precision Medicine



Clinical Trials

Translational Research & Clinical Trials, Advanced Biomarker Discovery (¥)

Diagnostics

Path from Translational

Research to CDx on the

Same Platform



Biobanks & Databases

Enabling Comprehensive Tumor Immuno-Genomics Database




Personalized Diagnostics & Therapies

Genomics Engine for Personalized Cancer Therapies & Diagnostics



Proprietary Assay and Analytics for the Many Elements of Tumor Biology




Personalis customers can select features of the platform to meet their particular needs. An * denotes next-generation feature in development.



23


Differentiated Analytics Driven by Proprietary Content






Proprietary Sequencing Methods Achieve Superior Coverage and Gene Finishing

Coverage, depth and accuracy are key in oncology



Comprehensiveness Allows Customers to Better Understand Why Patients Respond


At an average cost of ~\$60,000 per patient in oncology clinical trials,¹ understanding why patients do or don't respond is critical



Personalis* Note: 1. Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies, 2013.

NeXT Liquid Biopsy Capabilities to Complement ImmunoID NeXT Tumor Profiling


Tissue is critical for immune cells and RNA, but cfDNA complements with new insights and serial time points




NeXT Liquid Biopsy (LB) Enables a Broader View of Tumor Biology Compared to Panels¹

NeXT LB covers substantially more genes relevant to immunotherapy

Note:




Mutations Found in Tissue Samples and cfDNA are Important for Drug Development



Numbers indicate variants detected in the tumor only, plasma only, or in both.




29



Creating an Ecosystem of NeXT Products Over Time that Synergize to Drive Value

Harnessing Machine Learning For Leading Advanced Analytics & Biomarkers


SHERPA Machine Learning Based Neoantigen Prediction NEOPS Composite Neoantigen Presentation Score DASH Machine Learning HLA LOH Tool



Figures from Personalis AACR 2020 Posters. Publication Manuscripts in Progress for the Above Findings.




31



Driving Pharma Diagnostics Opportunities with NeXT Dx and NeXT CDx


- Drive tighter relationships with Pharma and lead to additional translational business
- NeXT has the scalability to address today's markers and enable future I-O markers on a single platform





NeXT Dx : Diagnostic for Today, Data for the Future, from One Test

NeXT Dx is a Catalyst for Building NeXT DB Tumor Immuno-genomics Database







Population Sequencing – U.S. VA Million Veteran Program

Research program to help improve the lives of Veterans and is in a very early stage

National research program to learn how genes, lifestyle, and military exposures affect health and illness.

- Enrolling veterans nationwide at a rate of approximately 100,000 a year
- 825,000 veterans enrolled in program todate
- Overall enrollment goal has recently been increased to 2 million veterans¹

MILLION PROGRAM O Seattle New England Consorti O Portland Fargo Minneapolis C Sioux Falls 🛟 on 🗘 🖸 Milwauke Detroit CHines Re Salt Lake City Iowa City Pittsburg San Francisco Palo Alto napolis 🛟 O Washington, DO Cincinnati worth 🔿 Kan St. Louis Salem C Las Vegas ountain C Durhan Los Angeles 😋 🗤 Nashvil Salisbury C Albuquerqu Muskogee * Fayettevill Columbia Little Rock C Phoenix San Diego 🛟 Charleston Atlanta 💭 Birminghan Tuscalor C Tucsor O Dallas Shreveport 🖸 Gainesville O New Orleans C Houston San Antonio Tampa 😳 Bay Pines 😳 💭 Miami **MVP Enrollment Clinics** Honolulu 😒 🦯 C Actively Recruiting * Temporarily Closed Closed to Recruitment

* As of March 2020, the VA MVP temporarily suspended sample collection due to the COVID-19 pandemic

Personalis is the Whole Genome Sequencing Provider to U.S. VA Million Veteran Program

Long-term partner

Working together since 2012 with approximately \$175M of orders as of September 2020

Significant customer offering stability and scale 2020 Revenue of \$56.1M

1Q'21 Revenue of \$13.2M

Personalis is currently contracted

to deliver ~147,000 samples; has completed 115,000+ to date



MILLION VETERAN PROGRAM

DISCOVERY * INNOVATION * ADVANCEMENT

We have leveraged this experience sequencing germline whole genomes to introduce (2019) whole genome sequencing for cancer. We plan to leverage this further as a future option to detect ~20x more variants for NeXT Personal.

VA MVP Research – An Example of How Data is Used

VA research during the COVID-19 pandemic

In response to the COVID-19 pandemic, VA Research has undertaken a wide array of activities to support and advance VA's clinical and research missions and help Veterans affected by the disease. These efforts have focused on establishing and taking part in **clinical trials** and **data analysis projects** aimed at understanding and treating the disease. VA Research has coordinated closely with internal VA and external partners—such as other federal agencies, and pharmaceutical companies—to identify the areas in which VA's nationwide research capacity, resources, and infrastructure could make the greatest contribution

COVID-19 Data Analysis Project

- VA MVP has a racially and ethnically diverse participant population (~20% African American and 7% Hispanic); will analyze the influence of race and ethnicity on disease susceptibility, severity, and outcomes will be an integral part of the analyses.
- Examine the genetic basis of infection by SARS CoV-2;
- Complications of infection;
- Disease severity and outcomes;
- Identify disease mechanisms and new treatment targets for COVID-19





Strong Financial Profile and Historical Growth



Personalis[°] ^{1.}

Notes: 1. Includes cash, cash equivalents and short-term investments





Q1 2021 Overview

Biopharma & All Other Customers

Q1 2021: \$7.7M, +74% Y/Y Strong customer orders Q3 '19 – Q1 '21 following introduction of our NeXT platform

Population Sequencing (includes VA MVP)

Q1 2021: \$ 13.2M Samples already received for processing during the next 2+ quarters